FindTrial
Sign In

A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00774332
Enrollment
37
Registered
2008-10-17
Start date
2006-06-30
Completion date
2009-12-31
Last updated
2008-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia

Brief summary

A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

Detailed description

The feasibility will be evaluated in terms of complete remission rate, duration of complete remission, disease-free survival, overall survival, and toxicities.

Interventions

DRUGCODOX-M

Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine

Sponsors

Cooperative Study Group A for Hematology
Lead SponsorNETWORK

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients with relapsed/resistant acute lymphoblastic leukemia * Patients must be between 15 and 65 years of age. * Estimated life expectancy of more than 3 months * ECOG performance status of 2 or lower, Karnofsky scale \> 60 (see appendix I) * Adequate cardiac function (EF\>45%) on echocardiogram or MUGA scan * Adequate kidney function (estimated Ccr \>50 ml/min)

Exclusion criteria

* Patients with CNS involvement of leukemic blasts will not be excluded. * Patients with extramedullary relapse(s) only will be excluded.

Design outcomes

Primary

MeasureTime frame
Duration of complete remission, disease-free survival, overall survival, toxicities2009

Countries

South Korea

Contacts

Primary ContactJung-Hee Lee, doctor
jhleecr@amc.seoul.kr82-2-3010-5794

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026